Key takeaways
- 1 COPD-specific Medicare national coverage determination exists — home NIPPV (NCD 240.9); no NCD covers maintenance inhalers or biologics, confirming Part D adjudication (CMS Coverage database)
- >=300 blood eosinophil count (cells/uL) that anchors dupilumab prior-authorization criteria, mirroring BOREAS/NOTUS entry (FDA label; PMIDs 37272521, 38767614)
- $2,000 IRA Medicare Part D annual out-of-pocket cap effective 2025, which reshapes cost exposure for high-priced COPD biologics (CMS / Inflation Reduction Act)
There is no Medicare national coverage determination for COPD inhalers or biologics — access is decided plan-by-plan through Part D step-edits, specialty tiers, and eosinophil-gated prior authorization
COPD maintenance therapy is almost entirely a pharmacy-benefit category. The only COPD-specific Medicare national coverage determination is for home noninvasive positive-pressure ventilation (NCD 240.9) — confirming that inhaled triples, the new nebulized PDE inhibitor, and the injectable biologic are all adjudicated under Part D and commercial pharmacy benefits, where coverage is plan-specific rather than nationally set. That makes formulary tier, step-edit design, and prior-authorization criteria the real access levers.
For the incumbent triples, the control is a step edit through generic LAMA/LABA before a branded triple clears. For dupilumab, access mirrors the trial: prior authorization typically requires blood eosinophils >=300, established triple therapy, and an exacerbation history — a biomarker gate that structurally caps volume. Ensifentrine, as a first-in-class nebulized product, faces new-to-market blocks and step-through requirements, and was the subject of a 2024 ICER value assessment. Overlaying all of it, the IRA's Part D redesign (a $2,000 annual out-of-pocket cap from 2025) materially improves the adherence economics for high-cost biologic patients, while Medicare price negotiation is a live risk for high-spend inhaler brands.
US COPD access sorts by channel and control: step-edited triples, an eosinophil-gated biologic, a new-to-market nebulized PDE inhibitor, and an IRA overlay on all of them
| Product / category | Benefit / channel | Access control | List price (WAC, reported) | HTA / IRA note |
|---|---|---|---|---|
| Triple inhalers (Trelegy, Breztri) | Medicare Part D / commercial pharmacy benefit | Step edit through LAMA/LABA; branded formulary tier (typically tier 3) | ~$600-660 per month (reported WAC) | No NCD; Part D-adjudicated — in scope for future IRA negotiation cycles, brand selection set annually by CMS |
| Dupixent (dupilumab) | Part D / pharmacy benefit (self-injected) | Prior authorization: eosinophils >=300, on triple therapy, exacerbation history | ~$3,000 per month / ~$36K+ per year (reported list) | Eosinophil-gated PA; specialty tier; $2,000 Part D OOP cap improves patient economics |
| Ohtuvayre (ensifentrine) | Part D / pharmacy benefit (nebulized suspension) | Prior authorization / step after bronchodilators; new-to-market block risk | ~$2,950 per month launch WAC / ~$35K per year (reported) | Subject of 2024 ICER value assessment; nebulized delivery can create pharmacy-vs-DME channel friction |
| Roflumilast (generic) | Part D / pharmacy benefit (oral) | Low tier; reserved for severe chronic-bronchitis exacerbators; tolerability step | Generic — low cost | Oral PDE4; genericization removes it from meaningful pricing/HTA debate |
| Coverage anchor (reference point) | Medicare Part B — national coverage | Only COPD NCD = home NIPPV (NCD 240.9) | n/a | Confirms inhalers and biologics are Part D / plan-specific, not nationally determined |
| Part D redesign (structural) | Medicare Part D — IRA | Benefit redesign applies across all COPD drugs | n/a | $2,000 annual OOP cap (2025) lowers biologic cost exposure and improves adherence economics |
Sources: Coverage structure: CMS Medicare Coverage database — the only COPD-specific national coverage determination returned is NCD 240.9 (home NIPPV for chronic respiratory failure due to COPD); maintenance inhalers and biologics are Part D / plan-specific. Dupilumab eosinophil-gated criteria: FDA Dupixent label and verified BOREAS/NOTUS entry (PMIDs 37272521, 38767614). Ensifentrine HTA: Institute for Clinical and Economic Review (ICER) 2024 assessment of ensifentrine for COPD. IRA Part D redesign and $2,000 OOP cap: CMS / Inflation Reduction Act. WAC/list prices reflect publicly reported manufacturer figures (launch WAC and payer reporting).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How tight is the eosinophil-gated PA on dupilumab, and how much volume does it strip vs the label? • A prior-authorization teardown showing how eos >=300 + triple + exacerbation-history criteria narrow the payable population
- Where does a first-in-class nebulized product like ensifentrine land on formularies — pharmacy, DME, or split? • A channel and step-edit map plus the ICER value-assessment read that anchors payer pushback on price
- Which COPD brands carry real IRA negotiation exposure, and on what timeline? • A structured check of high-spend Part D COPD inhalers against CMS selected-drug lists, with the patent-thicket / device-lifecycle context
What's inside
-
1 · No COPD-Specific NCD: Why Part D and Commercial PBMs Adjudicate Every Inhaler and Biologic 4 pp
- The single COPD-specific Medicare NCD, 240.9 for home NIPPV, confirming inhalers and biologics are Part D/plan-adjudicated, not nationally set
- Why formulary tier, step-edit design, and PA criteria are the real access levers for COPD therapy
-
2 · The LAMA/LABA Step Edit Gating Branded Triple Inhalers 5 pp
- How generic LAMA/LABA step edits control access before a branded triple (Trelegy, Breztri) clears, at ~$600-660/month WAC
- The tier-3 branded formulary placement typical of incumbent triple inhalers
-
3 · List vs Net: Triple, Dupilumab and Ensifentrine Pricing 4 pp
- Reported list WAC comparison: ~$600-660/month triples vs ~$3,000/month dupilumab vs ~$2,950/month ensifentrine launch price
- How specialty-tier placement and rebate dynamics separate list from net cost across the three product classes
-
4 · Eosinophil-Gated Biologic Access and Ensifentrine's 2024 ICER Review 4 pp
- The dupilumab PA criteria mirroring trial entry: eosinophils >=300, established triple therapy, and exacerbation history
- Ensifentrine's 2024 ICER value assessment and its new-to-market step-through requirements as a first-in-class nebulized product
-
5 · The IRA Overlay: $2,000 Part D Cap and Negotiation Risk for High-Spend Inhalers 5 pp
- How the $2,000 annual Part D out-of-pocket cap effective 2025 materially improves adherence economics for high-cost biologic patients
- The live Medicare price-negotiation risk facing high-spend inhaler brands under future CMS selected-drug lists
-
6 · Access Strategy Across the Triple, Biologic and Nebulized Channels 3 pp
- How pharmacy-versus-DME channel friction shapes access for a nebulized product like ensifentrine
- The distinct step-edit and PA strategy required across triple, biologic, and nebulized channels
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers US COPD payer & hta built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US COPD Payer & HTA sources: CMS Medicare Coverage database (NCDs), FDA labels, ICER assessments, CMS/IRA Part D guidance, and reported manufacturer pricing.
- CMS national coverage search confirmed live: the only COPD-specific NCD is 240.9 (home NIPPV); no NCD governs maintenance inhalers or biologics, which route through Part D.
- COPD maintenance inhalers and biologics are Part D-adjudicated, the benefit category subject to Medicare drug-price negotiation under the IRA; specific brand selection is announced annually via the CMS selected-drug list.
- Reported WAC/list prices (triples ~$600–660/mo; dupilumab ~$3,000/mo; ensifentrine ~$2,950/mo launch WAC) reflect publicly reported manufacturer list prices.
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: the CMS Medicare coverage database, FDA labels, ICER assessments, CMS Part D guidance, and reported manufacturer pricing. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.